Sun Pharma just posted ₹58,220 crore in FY26 revenue — up 12% — and in the same breath announced it's buying Organon & Co. for $3.99 billion to go big in women's health.
Two headlines.
One story.
Here's the twist nobody's talking about enough:
Sun Pharma isn't really a "generics company" anymore.
Back in FY18, Innovative Medicines — patent-protected, higher-margin drugs — made up just 7.3% of Sun Pharma's sales.
Today?
22%.
That segment has compounded at 24% annually since FY21, more than double the company's overall growth rate.
One drug is doing the heavy lifting though:
💰 Ilumya alone pulled in $796 million in FY26
🧬 That's over half of the entire Innovative Medicines revenue
⚠️ Five pipeline drugs are still years away from meaningful sales
While investors were still digesting the annual numbers, Sun Pharma dropped a bigger move.
$14 a share.
$3.99 billion in equity value.
$11.75 billion enterprise value — India's largest-ever pharma outbound acquisition.
The prize? A global women's health and biosimilars business that instantly makes Sun Pharma the world's 7th-biggest biosimilar player and a top-3 name in women's health.
The market liked it. Fast.
Sun Pharma's stock jumped over 7% on the news.
Organon's shares? Up 17%.
EBITDA grew 16%. Net profit grew just 5%.
₹920 crore in one-off provisions ate into the gap — a pattern that's shown up before in Sun Pharma's books.
And gross debt more than doubled, up 118% year-on-year, as the Organon financing kicks in.
At 40 times earnings, the market is already betting Sun Pharma can pull off two things at once:
keep the Innovative Medicines engine running beyond one blockbuster drug, and
integrate an $11.75 billion acquisition cleanly.
That's a lot riding on execution.
That's all for now!
